Tag: Cancer: Rectal

In one health system, including personalized risk in a decision aid or provider notification increased uptake of stool testing

Positive associations seen for celiac disease, SLE, T1D with pancreatic, esophageal, colon, liver, and hepatobiliary cancers

Findings compared with three opt-in screening strategies among average-risk adults aged 45 to 49 years

Second study shows increase in up-to-date CRC screening prevalence

Just under half of patients receiving an abnormal blood test have follow-up colonoscopy in the short term

In study, patients with CRC as the only malignancy had more frequent liver and lung metastases and received systemic adjuvant treatments more often

Multitarget stool DNA testing was cost-effective relative to no screening, but CT colonography is cost-saving

In an average-risk colorectal cancer screening population, a blood-based circulating tumor DNA test is feasible

Only risk of any adenoma differed between the groups

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations